Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Stabilized plasmid-lipid particles: construction and characterization.

J J Wheeler1, L Palmer, M Ossanlou

  • 1Inex Pharmaceuticals Corporation, Burnaby, BC, Canada.

Gene Therapy
|August 6, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Protein domain movement involved in binding of belinostat and HPOB as inhibitors of histone deacetylase 6 (HDAC6): a hybrid automated-interactive docking study.

Journal of computer-aided molecular design·2025
Same author

Understanding HCBS utilization: The role of disability onset age and length of disability.

Disability and health journal·2025
Same author

Place-based household vouchers for locally supplied fruit and vegetables: the Fresh Street pilot cluster randomised controlled trial.

BMC public health·2025
Same author

Breakthrough cancer pain management: mixed-methods study of health care professionals.

BMJ supportive & palliative care·2024
Same author

The 60-year evolution of lipid nanoparticles for nucleic acid delivery.

Nature reviews. Drug discovery·2024
Same author

A systematic review of qualitative research exploring patient and health professional perspectives of breakthrough cancer pain.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2023
Same journal

Improving the precision of AAV lung gene therapy for SP-B deficiency using computationally derived lung-specific promoters.

Gene therapy·2026
Same journal

Recent advancements in improving cross-species applicability of bioengineered AAV capsids.

Gene therapy·2026
Same journal

Assessment of F/HN-pseudotyped lentiviral vector following intravenous delivery to mice.

Gene therapy·2026
Same journal

Applications of genome editing technologies in the treatment of human diseases.

Gene therapy·2026
Same journal

High resolution ES-DMA quantifies AAV capsid DNA content by electrical mobility to mass correlation.

Gene therapy·2026
Same journal

AAV8-mediated mouse/human PROC expression rescues thrombophilia in hereditary protein C-deficient mice.

Gene therapy·2026
See all related articles

Researchers developed stabilized plasmid-lipid particles (SPLP) for gene therapy. These particles protect DNA and show potential for systemic delivery, with transfection efficiency tunable by particle surface chemistry.

Area of Science:

  • Biotechnology
  • Nanotechnology
  • Gene Therapy

Background:

  • Gene delivery systems are crucial for gene therapy.
  • Protecting nucleic acids from degradation is a key challenge.
  • Lipid-based nanoparticles offer a promising platform for gene delivery.

Purpose of the Study:

  • To develop a novel method for encapsulating plasmid DNA into lipid nanoparticles.
  • To create stabilized plasmid-lipid particles (SPLP) with enhanced stability and transfection capabilities.
  • To investigate the role of surface modification in SPLP functionality for gene delivery.

Main Methods:

  • A detergent dialysis procedure was employed for encapsulation.
  • Poly(ethyleneglycol) (PEG) coating was used for particle stabilization.

Related Experiment Videos

  • Varying cationic lipid content (e.g., DODAC) and PEG anchor chain length were tested.

    • Main Results:

    • SPLP averaged 70 nm in diameter, encapsulating one plasmid per particle.
    • Particles demonstrated complete protection against serum nucleases and DNase I.
    • Encapsulation efficiency correlated with DODAC content (optimal at 5-10 mol%).
    • Transfection efficiency was modulated by the acyl chain length of the ceramide anchor for PEG, affecting PEG dissociation.

    Conclusions:

    • The described method successfully produces stable, nuclease-resistant plasmid-lipid particles (SPLP).
    • SPLP surface properties, particularly PEG coating dissociation, can be tuned to control transfection competence.
    • SPLP show significant potential as systemic gene delivery vehicles for gene therapy applications.